Correlation Between Astrazeneca PLC and Gilead Sciences

By analyzing existing cross correlation between Astrazeneca PLC and Gilead Sciences, you can compare the effects of market volatilities on Astrazeneca PLC and Gilead Sciences and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Astrazeneca PLC with a short position of Gilead Sciences. Check out your portfolio center. Please also check ongoing floating volatility patterns of Astrazeneca PLC and Gilead Sciences.

Specify exactly 2 symbols:

Can any of the company-specific risk be diversified away by investing in both Astrazeneca PLC and Gilead Sciences at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Astrazeneca PLC and Gilead Sciences into the same portfolio, which is an essential part of the fundamental portfolio management process.

Diversification Opportunities for Astrazeneca PLC and Gilead Sciences

-0.1
  Correlation Coefficient
Astrazeneca PLC
Gilead Sciences

Good diversification

The 3 months correlation between Astrazeneca and Gilead is -0.1. Overlapping area represents the amount of risk that can be diversified away by holding Astrazeneca PLC and Gilead Sciences Inc in the same portfolio assuming nothing else is changed. The correlation between historical prices or returns on Gilead Sciences and Astrazeneca PLC is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Astrazeneca PLC are associated (or correlated) with Gilead Sciences. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Gilead Sciences has no effect on the direction of Astrazeneca PLC i.e. Astrazeneca PLC and Gilead Sciences go up and down completely randomly.

Pair Corralation between Astrazeneca PLC and Gilead Sciences

Considering the 30-days investment horizon, Astrazeneca PLC is expected to generate 0.6 times more return on investment than Gilead Sciences. However, Astrazeneca PLC is 1.66 times less risky than Gilead Sciences. It trades about 0.11 of its potential returns per unit of risk. Gilead Sciences is currently generating about 0.0 per unit of risk. If you would invest  4,868  in Astrazeneca PLC on June 13, 2020 and sell it today you would earn a total of  508.00  from holding Astrazeneca PLC or generate 10.44% return on investment over 30 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Astrazeneca PLC  vs.  Gilead Sciences Inc

 Performance (%) 
      Timeline 
Astrazeneca PLC 
77

Astrazeneca PLC Risk-Adjusted Performance

Compared to the overall equity markets, risk-adjusted returns on investments in Astrazeneca PLC are ranked lower than 7 (%) of all global equities and portfolios over the last 30 days. Although quite unsteady forward indicators, Astrazeneca PLC may actually be approaching a critical reversion point that can send shares even higher in August 2020.
Gilead Sciences 
00

Gilead Sciences Risk-Adjusted Performance

Over the last 30 days Gilead Sciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound fundamental drivers, Gilead Sciences is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders.

Astrazeneca PLC and Gilead Sciences Volatility Contrast

 Predicted Return Density 
      Returns 
Check out your portfolio center. Please also try Commodity Channel Index module to use commodity channel index to analyze current equity momentum.


 
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page